Evidence map›Paper›PMID 40178918›Full record

ArticleJCI insight2025

Dipeptidase-1-knockout mice develop invasive tumors with features of microsatellite-unstable colorectal cancer.

Sarah E Glass, Matthew E Bechard, Zheng Cao, Radhika Aramandla, Ping Zhao, Samuel T Ellis, Emily H Green, Elizabeth G Fisher, Ryan T Smith, Chelsie K Sievers and 14 more

Abstract read
In one paragraph

Article in JCI insight, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Sarah E GlassDepartment of Cell and Developmental Biology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Matthew E BechardDepartment of Medicine.
Zheng CaoDepartment of Medicine.
Radhika AramandlaDepartment of Medicine.
Ping ZhaoDepartment of Medicine.
Samuel T EllisDepartment of Medicine.
Emily H GreenEpithelial Biology Center.
Elizabeth G FisherEpithelial Biology Center.
Ryan T SmithDepartment of Medicine.
Chelsie K SieversDepartment of Medicine.
Maria Johnson IrudayamDepartment of Medicine.
Frank RevettaDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
M Kay WashingtonDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Gregory D AyersDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Cody N HeiserEpithelial Biology Center.
Alan J SimmonsDepartment of Cell and Developmental Biology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Yanwen XuDepartment of Cell and Developmental Biology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Yu WangDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Annika WindonDepartment of Pathology and Laboratory Medicine, Weill Cornell Medical Center, New York, New York, USA.
Martha J ShrubsoleDepartment of Medicine.
Nicholas O MarkhamDepartment of Medicine.
Qi LiuDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Ken S LauDepartment of Cell and Developmental Biology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Robert J CoffeyDepartment of Cell and Developmental Biology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.

Funding

Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Ben Ho Park · 1995 to 2026
$172.8M
Translational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MARY Kay WASHINGTON · 2002 to 2026
$29.9M
Vanderbilt-Ingram Cancer Center SPORE in Gastrointestinal CancerP50CA236733 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI STEPHEN W. FESIK · 2019 to 2026
$19.6M
Roles for Supermeres in CRC ProgressionP01CA229123 · NCI · VANDERBILT UNIVERSITY · PI Alissa M Weaver · 2020 to 2026
$12.9M
Shaping the Microenvironment by DPEP1 Facilitates Adenoma ProgressionU54CA274367 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Ken S Lau · 2022 to 2026
$9.7M
Integrated approach to study early and late events in colonic neoplasia: mouse to manR35CA197570 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Robert J. Coffey · 2017 to 2026
$9.4M
BIOCHEMICAL &CHEMICAL TRAINING FOR CANCER RESEARCHT32CA009582 · NCI · VANDERBILT UNIVERSITY · PI David K Cortez · 1987 to 2026
$8.8M
Tuft cell heterogeneity in function, lineage, and structure in ileal inflammatory diseaseR01DK103831 · NIDDK · VANDERBILT UNIVERSITY · PI LAU, KEN S · 2016 to 2024
$4.4M
Tumor Markers and Recurrent Adenomas: A Follow-up StudyR01CA097386 · NCI · VANDERBILT UNIVERSITY · PI ZHENG, WEI · 2002 to 2006
$3.6M
Uncovering exRNA and protein determinants of secreted vesicle heterogeneity by flow cytometric purification of vesicle subsets from cells and plasmaUH3CA241685 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI CHAREST, ALAIN, COFFEY, ROBERT J. · 2021 to 2022
$2.1M
Diet, Genetics, Epigenetics and Colorectal Adenoma Risk.K07CA122451 · NCI · VANDERBILT UNIVERSITY · PI SHRUBSOLE, MARTHA J. · 2007 to 2011
$655k
Deleted in malignant brain tumors 1 (DMBT1) expression and impact on colonic dysplasiaF31CA294983 · NCI · VANDERBILT UNIVERSITY · PI Emily H Green · 2024 to 2026
$105k
NCI NIH HHS F31 CA294983NCI NIH HHS K07 CA122451NCI NIH HHS P01 CA229123NCI NIH HHS P30 CA068485NCI NIH HHS P50 CA236733NCI NIH HHS R01 CA097386NCI NIH HHS R35 CA197570NCI NIH HHS T32 CA009582NCI NIH HHS U54 CA274367NCI NIH HHS UH3 CA241685NIDDK NIH HHS P30 DK058404NIDDK NIH HHS R01 DK103831
6 · The paper itself

Abstract

Dipeptidase-1 (DPEP1) is highly upregulated in colorectal cancer (CRC), with its enzymatic function linked to invasion and metastasis. More recently, DPEP1 was found to serve as a receptor for neutrophils when expressed by activated endothelial cells. It is unknown whether neutrophils bind to DPEP1-expressing CRC cells and whether this impacts features of CRC. Neutrophils have been shown to be tumor promoting in cancers including CRC, where they act to exclude CD8+ T cells. Herein, we show that neutrophils bind DPEP1-expressing CRC cells. In addition, DPEP1 is preferentially expressed in microsatellite-stable (MSS) CRCs, in which there are a paucity of CD8+ T cells, whereas DPEP1 is negatively correlated with microsatellite-unstable (MSI-H) CRCs, which are T cell rich and are more responsive to immunotherapy. Remarkably, carcinogen-treated Dpep1-null mice develop multiple, large, plaque-like, locally invasive adenocarcinomas and squamous cell cancers in the distal colon. These adenocarcinomas exhibit a marked reduction in neutrophils and an influx CD8+ T cells, along with reduced expression of mismatch repair proteins, consistent with features of MSI-H CRC. These results establish DPEP1's importance in maintaining MSS CRC and its ability to shape the tumor microenvironment.

Indexed as

Colorectal NeoplasmsDipeptidasesMicrosatellite InstabilityAdenocarcinomaAnimalsCD8-Positive T-LymphocytesFemaleHumansMaleMiceMice, KnockoutNeoplasm InvasivenessNeutrophilsDipeptidasesCancerCell biologyOncology

Identifiers

PMID40178918
PMCPMC12128987

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.